Sjögren Syndrome with Systemic Glandular Involvement and Parotid or Salivary Gland Swelling — Active Systemic Disease
This protocol addresses a specific and clinically significant presentation of Sjögren syndrome: systemic glandular involvement accompanied by parotid or salivary gland swelling, with evidence of active systemic disease as indicated by a clinESSDAI score of 1 or higher.
Clinical Scenario
Patients present with Sjögren syndrome showing systemic glandular involvement — including parotid or salivary gland swelling — alongside active systemic disease (clinESSDAI score ≥ 1). Systemic disease is defined as involvement that affects, or has affected, any organ or system included in the clinESSDAI score.
Therapeutic Approach
The systemic management of Sjögren syndrome at this level of involvement may follow a structured sequential or combined strategy incorporating glucocorticoids, immunosuppressive agents, and biologic therapies, guided by the degree of systemic activity.
Treatment & Goals
In this clinical scenario, biologic infusion therapy is among the options addressed in the structured regimen. The primary treatment goal is a meaningful reduction in the global ESSDAI score — specifically a decrease of 3 or more points as the defined marker of response.
The complete agent selection, sequencing, and full clinical parameters are available in the protocol below.
References
DOI: 10.1136/annrheumdis-2019-216114
- Systemic disease: Disease involvement that affects or has affected any of the organs/systems included in the clinESSDAI score.
- The systemic organ-specific therapeutic approach may follow, as a general rule, the sequential (or combined) use of GCs, immunosuppressive agents and biologics.
- The use of rituximab may be considered in patients with severe, refractory systemic disease.
- With respect to the definition of the therapeutic response in systemic SjS, the TF recommends using a reduction of >=3 points in the global ESSDAI score.
View source ↗